bluuebunny/crossref_metadata_2025_split huggingface dataset:
A functional outcome prediction model of acute traumatic spinal cord injury based on extreme gradient boost
Authors: Sizheng Zhan , Boxuan Huang , Feng Xue , Dianying Zhang 
Published: October 2022

Abstract
Objective
We aimed to construct a nonlinear regression model through Extreme Gradient Boost (XGBoost) to predict functional outcome 1 year after surgical decompression for patients with acute spinal cord injury (SCI) and explored the importance of predictors in predicting the functional outcome.

Methods
We prospectively enrolled 249 patients with acute SCI from 5 primary orthopedic centers from June 1, 2016, to June 1, 2020. We identified a total of 6 predictors with three aspects: (1) clinical characteristics, including age, American Spinal Injury Association (ASIA) Impairment Scale (AIS) at admission, level of injury and baseline ASIA motor score (AMS); (2) MR imaging, mainly including Brain and Spinal Injury Center (BASIC) score; (3) surgical timing, specifically comparing whether surgical decompression was received within 24 h or not. We assessed the SCIM score at 1 year after the operation as the functional outcome index. XGBoost was used to build a nonlinear regression prediction model through the method of boosting integrated learning.

Results
We successfully constructed a nonlinear regression prediction model through XGBoost and verified the credibility. There is no significant difference between actual SCIM and nonlinear prediction model (t = 0.86, P = 0.394; Mean ± SD: 3.31 ± 2.8). The nonlinear model is superior to the traditional linear model (t = 6.57, P < 0.001). AMS and age played the most important roles in constructing predictive models. There is an obvious correlation between AIS, AMS and BASIC score.

Conclusion
We verified the feasibility of using XGBoost to construct a nonlinear regression prediction model for the functional outcome of patients with acute SCI, and proved that the predictive performance of the nonlinear model is better than the traditional linear regression prediction model. Age and baseline AMS play the most important role in predicting the functional outcome. We also found a significant correlation between AIS at admission, baseline AMS and BASIC score.

Trial registration

ClinicalTrials.gov identifier: NCT03103516.
Reduced activity of parvalbumin-positive interneurons in the posterior parietal cortex causes visually dominant multisensory decisions in freely navigating mice
Authors: Choi Ilsong , Lee Seung-Hee 
Published: October 2022

AbstractMultisensory integration is vital for animals to make optimal decisions in a complicated sensory environment. However, the neural mechanisms for flexible multisensory behaviors are not well understood. Here, we found that mice exhibit auditory-dominant decisions in the head-fixed and stationary state and switch to make visual-dominant decisions in the freely navigating state to resolve audiovisual conflicts. To understand the neural mechanism of the state-dependent switch in multisensory decisions, we performed in vivo calcium imaging of parvalbumin-expressing (PV+) inhibitory neurons in the posterior parietal cortex (PPC), which are known to mediate auditory dominance in the resolution of audiovisual conflicts, in mice on the treadmill. In the stationary state, the PPC PV+neurons showed similar amounts of evoked activity in responses to auditory and visual stimuli and enhanced responses to the multisensory audiovisual stimuli. Conversely, when mice were running on a treadmill, the PV+neurons lost auditory responses and did not show any multisensory enhancement in their activity. When we optogenetically activated the PPC PV+neurons in mice freely navigating the T-maze, the mice made more auditory-dominant decisions without changes in unisensory decisions. Our data demonstrate that the PPC PV+neurons lost their ability to integrate auditory information with the visual one during active navigation. This modulation of the PPC PV+neuron activity is critical for animals to make adaptive multisensory decisions according to their behavioral states.
Analysis of influencing factors of passes in the chinese super league
Authors: Zeng Yue , Zhang Hui 
Published: October 2022

Abstract
Background
In football matches, passing is an important means of organizing attacks, creating shots, changing tactics, and achieving tactical objectives and is a frequently used technique. The purpose of the study was to explore the relevant factors that affect passes in the Chinese Super League (CSL) in different game contexts.

Methods
A total of 1,440 matches (2,880 samples) of 24 teams participating in the CSL in the 2014–2019 seasons were selected as the research object, and a mixed linear model was constructed to analyse the influencing factors of passes.

Results
(a) The passing success rate and the total number of forward passes were greatly affected by the stage of the season; (b) except for the passing success rate in the 30 m attack area, all other pass indicators in the home matches were significantly higher than those in the away matches; (c) the number of passes in the 30 m attack area was mainly affected by the team level (table position quartile); the higher the team level, the greater the number of passes in the 30 m attack area; (d) all passing indices for the matches between the first eight and the last eight were significantly greater than the matches between the first eight; (e) the passing success rate in the 30 m attack area in winning matches was higher than that in drawn matches; (f) the number of forward passes was significantly greater in matches won by two or more goals, and the number of defender passes was significantly greater in losing matches.

Conclusion
The various passing indices of the CSL were affected by different game contexts (including season stage, venue, team level, match type and match outcome), and understanding these influencing factors of passes will help coaches and players better understand football matches.
PACADI: translation and adaptation of a Swedish-language version of the pancreatic cancer disease impact score
Authors: Andersson Thomas , Fagevik Olsén Monika , Al Nouh Micheline , Bratlie Svein Olav 
Published: October 2022

Abstract
Objective
The Norwegian pancreatic cancer disease impact score (PACADI) is a digitalized analogue questionnaire that assesses different disease-specific symptoms. There is a need of translations of it into other languages. Therefore, the aim of this article is to describe the translation process of a Swedish version of PACADI and present its validity to EORCT QLQ PAN26. The self-administered questionnaire PACADI was translated according to guidelines and assessed by an expert panel of health care personnel. The test of its validity was performed with the disease-specific questionnaire for EORCT QLQ PAN26. Both questionnaires were completed by 66 subjects with pancreatic cancer, either before, at discharge or three months after surgery.

Result
The results between the groups indicate that patients suffer from different symptoms at different times. The correlations between the different symptoms of the two questionnaires were fair to good. In conclusion, PACADI and QLQ PAN 26 have a good correlation and PACADI can be used in clinical practise.
Effect of internet-based counselling with a cognitive-behavioural approach on premenstrual syndrome
Authors: Borji-Navan Sanam , Mohammad-Alizadeh-Charandabi Sakineh , Esmaeilpour Khalil , Mirghafourvand Mojgan 
Published: October 2022

Abstract
Objectives
To assess the effect of internet-based counselling with a cognitive-behavioural approach on symptom severity of women with premenstrual syndrome (PMS) and their quality of life during the perimenstrual and late follicular phases of the menstrual cycle. Moreover, the PMS-related disability and attitude toward menstruation were investigated as secondary outcomes.

Data description
We provide data generated in a randomized controlled trial with two-parallel arms carried out on 92 female university students aged 18–35 years who had moderate to severe PMS, residing at halls of the Tabriz University of Medical Sciences. PMS severity was assessed during two menstrual cycles before intervention (baseline) and during two cycles just after ending the two-month intervention using Daily Record of Severity of Problems (DRSP) and the quality of life using the Quality of Life Enjoyment and Satisfaction Questionnaire—Short Form (Q-LES-Q-SF) on days 1–2 and 11–13 of the menstrual cycle at the baseline and post-intervention. Also, the PMS-related disability was assessed using Sheehan Disability Scale (SDS) and attitude toward menstruation using Menstrual Attitude Questionnaire (MAQ) at the baseline and post-intervention. Participant satisfaction and views on intervention effectiveness were also assessed using a single Likert question.
Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias
Authors: Baiardi Simone , Quadalti Corinne , Mammana Angela , Dellavalle Sofia , Zenesini Corrado , Sambati Luisa , Pantieri Roberta , Polischi Barbara , Romano Luciano , Suffritti Matteo , Bentivenga Giuseppe Mario , Randi Vanda , Stanzani-Maserati Michelangelo , Capellari Sabina , Parchi Piero 
Published: October 2022

AbstractBackgroundIncreasing evidence supports the use of plasma biomarkers of neurodegeneration and neuroinflammation to screen and diagnose patients with dementia. However, confirmatory studies are required to demonstrate their usefulness in the clinical setting.MethodsWe evaluated plasma and cerebrospinal fluid (CSF) samples from consecutive patients with frontotemporal dementia (FTD) (n= 59), progressive supranuclear palsy (PSP) (n= 31), corticobasal syndrome (CBS) (n= 29), dementia with Lewy bodies (DLB) (n= 49), Alzheimer disease (AD) (n= 97), and suspected non-AD physiopathology (n= 51), as well as plasma samples from 60 healthy controls (HC). We measured neurofilament light chain (NfL), phospho-tau181 (p-tau181), and glial fibrillary acid protein (GFAP) using Simoa (all plasma biomarkers and CSF GFAP), CLEIA (CSF p-tau181), and ELISA (CSF NfL) assays. Additionally, we stratified patients according to the A/T/N classification scheme and the CSF α-synuclein real-time quaking-induced conversion assay (RT-QuIC) results.ResultsWe found good correlations between CSF and plasma biomarkers for NfL (rho = 0.668,p< 0.001) and p-tau181 (rho = 0.619,p< 0.001). Plasma NfL was significantly higher in disease groups than in HC and showed a greater increase in FTD than in AD [44.9 (28.1–68.6) vs. 21.9 (17.0–27.9) pg/ml,p< 0.001]. Conversely, plasma p-tau181 and GFAP levels were significantly higher in AD than in FTD [3.2 (2.4–4.3) vs. 1.1 (0.7–1.6) pg/ml,p< 0.001; 404.7 (279.7–503.0) vs. 198.2 (143.9–316.8) pg/ml,p< 0.001]. GFAP also allowed discriminating disease groups from HC. In the distinction between FTD and AD, plasma p-tau181 showed better accuracy (AUC 0.964) than NfL (AUC 0.791) and GFAP (AUC 0.818). In DLB and CBS, CSF amyloid positive (A+) subjects had higher plasma p-tau181 and GFAP levels than A− individuals. CSF RT-QuIC showed positive α-synuclein seeding activity in 96% DLB and 15% AD patients with no differences in plasma biomarker levels in those stratified by RT-QuIC result.ConclusionsIn a single-center clinical cohort, we confirm the high diagnostic value of plasma p-tau181 for distinguishing FTD from AD and plasma NfL for discriminating degenerative dementias from HC. Plasma GFAP alone differentiates AD from FTD and neurodegenerative dementias from HC but with lower accuracy than p-tau181 and NfL. In CBS and DLB, plasma p-tau181 and GFAP levels are significantly influenced by beta-amyloid pathology.
Modifiable and non-modifiable risk factors of dementia on midlife cerebral small vessel disease in cognitively healthy middle-aged adults: the PREVENT-Dementia study
Authors: Low Audrey , Prats-Sedano Maria A. , McKiernan Elizabeth , Carter Stephen F. , Stefaniak James D. , Nannoni Stefania , Su Li , Dounavi Maria-Eleni , Muniz-Terrera Graciela , Ritchie Karen , Lawlor Brian , Naci Lorina , Malhotra Paresh , Mackay Clare , Koychev Ivan , Ritchie Craig W. , Markus Hugh S. , O’Brien John T. 
Published: October 2022

Abstract
Background
Considerable overlap exists between the risk factors of dementia and cerebral small vessel disease (SVD). However, studies remain limited to older cohorts wherein pathologies of both dementia (e.g. amyloid) and SVD (e.g. white matter hyperintensities) already co-exist. In younger asymptomatic adults, we investigated differential associations and interactions of modifiable and non-modifiable inherited risk factors of (future) late-life dementia to (present-day) mid-life SVD.

Methods
Cognitively healthy middle-aged adults (aged 40–59; mean 51.2 years) underwent 3T MRI (n = 630) as part of the PREVENT-Dementia study. To assess SVD, we quantified white matter hyperintensities, enlarged perivascular spaces, microbleeds, lacunes, and computed composite scores of SVD burden and subtypes of hypertensive arteriopathy and cerebral amyloid angiopathy (CAA). Non-modifiable (inherited) risk factors were APOE4 status and parental family history of dementia. Modifiable risk factors were derived from the 2020 Lancet Commission on dementia prevention (early/midlife: education, hypertension, obesity, alcohol, hearing impairment, head injuries). Confirmatory factor analysis (CFA) was used to evaluate the latent variables of SVD and risk factors. Structural equation modelling (SEM) of the full structural assessed associations of SVD with risk factors and APOE4*risk interaction.

Results
In SEM, the latent variable of global SVD related to the latent variable of modifiable midlife risk SVD (β = 0.80, p = .009) but not non-modifiable inherited risk factors of APOE4 or family history of dementia. Interaction analysis demonstrated that the effect of modifiable risk on SVD was amplified in APOE4 non-carriers (β = − 0.31, p = .009), rather than carriers. These associations and interaction effects were observed in relation to the SVD subtype of hypertensive arteriopathy, rather than CAA. Sensitivity analyses using separate general linear models validated SEM results.

Conclusions
Established modifiable risk factors of future (late-life) dementia related to present-day (mid-life) SVD, suggesting that early lifestyle modifications could potentially reduce rates of vascular cognitive impairment attributed to SVD, a major ‘silent’ contributor to global dementia cases. This association was amplified in APOE4 non-carriers, suggesting that lifestyle modifications could be effective even in those with genetic predisposition to dementia.
Baicalin acts as an adjuvant to potentiate the activity of azithromycin against Staphylococcus saprophyticus biofilm: an in vitro, in vivo, and molecular study
Authors: Wang Jinli , Li Siya , Meng Jinwu , Zhu Jinyue , Qiu Tianxin , Wang Wenjia , Ding Jinxue , Liu Zhenguang , Li Kun , lqbal Mujahid , Wang Deyun , Wu Yi , Liu Jiaguo 
Published: October 2022

AbstractStaphylococcus saprophyticus is frequently involved in various difficult-to-treat infections due to the formation of biofilms. To identify useful antibiofilm strategies, this study explored the efficacy and mechanism of baicalin in enhancing the ability of azithromycin against multidrug-resistant Staphylococcus saprophyticus-Liu-2016-Liyang, China-francolin (MDRSS) biofilms in vitro and in vivo. When azithromycin was used in combination with baicalin, the minimum inhibitory concentration in biofilm (MICB) for azithromycin decreased 4- to 512-fold. Compared with the azithromycin and baicalin groups, the combination of azithromycin and baicalin could not reduce the biofilm biomass, but the dispersion rates of biofilm were decreased and the bactericidal ability was increased. Furthermore, the relative transcript levels of WalK/R system-related genes were upregulated by the addition of baicalin or azithromycin plus baicalin compared with that of the azithromycin and blank control groups. The strong correlation relationship between the WalK/R system and the bactericidal index demonstrated that baicalin enhanced the bactericidal effect of azithromycin on MDRSS biofilms by modulating the WalK/R system. In the mouse cutaneous infection model, the combination of azithromycin and baicalin succeeded in eradicating MDRSS and decreasing pathological injuries. This study indicated that baicalin has the potential to be an adjuvant to enhance the antimicrobial activity of azithromycin against MDRSS in the biofilm form by modulating the WalK/R system.
Chicken miR-126-5p negatively regulates antiviral innate immunity by targeting TRAF3
Authors: Wang Jie , Cheng Yuqiang , Wang Longlong , Sun Aixi , Lin Zhenyu , Zhu Wenxian , Wang Zhaofei , Ma Jingjiao , Wang Henan , Yan Yaxian , Sun Jianhe 
Published: October 2022

AbstractInnate immunity plays an essential role in preventing the invasion of pathogenic microorganisms. However, innate immunity is a double-edged sword, whose excessive activation is detrimental to immune homeostasis and even leads to a “cytokine storm” of the infected host. The host develops a series of negative regulatory mechanisms to balance the immune response. Here, we report a negative regulatory mechanism of chicken innate immunity mediated by miRNA. In the GEO database, we found that miR-126-5p was markedly up-regulated in chickens infected by RNA viruses. Upregulation of miR-126-5p by RNA virus was then further shown via both a cell model and in vivo tests. Overexpression of miR-126-5p significantly inhibited the expression of interferon and inflammatory cytokine-related genes induced by RNA viruses. The opposite result was achieved after the knockdown of miR-126-5p expression. Bioinformatics analysis identified TRAF3 as candidate target gene of miR-126-5p. Experimentally, miR-126-5p can target TRAF3, as shown by the effects of miR-126-5p on the endogenous expression of TRAF3, and by the TRAF3 3'UTR driven luciferase reporter assay. Furthermore, we demonstrated that miR-126-5p negatively regulated innate immunity by blocking the MAVS-TRAF3-TBK1 axis, with a co-expression assay. Overall, our results suggest that miR-126-5p is involved in the negative regulation of chicken innate immunity, which might contribute to maintaining immune balance.
Local time and longitudinal variation of the ionospheric radial current: swarm observations and TIE–GCM simulations
Authors: Wang Hui , Xia Hao , Zhang Kedeng , Zhong Yunfang , Qian Chenyu 
Published: October 2022

AbstractBased on the high-precision vector magnetic field data of Swarm A and C satellites, we perform a statistical analysis of the diurnal and longitudinal variations of the ionospheric radial current (IRC) in the F layer at the magnetic equator from 2014 to 2018. The observations are compared with the simulations based on the Thermosphere–Ionosphere Electrodynamics–General Circulation Model (TIE–GCM). It is found that the noon IRC is radially outward, whereas the dusk IRC is radially inward. The time of the change from the inward to the outward direction occurred is earlier in June than in other seasons. The TIE–GCM results show that low atmospheric tides have an important effect on the seasonal change in the reverse time. The noon IRC is weakened primarily by the polarization current from migrating tides. The dusk IRC is mainly weakened by polarization current from nonmigrating tides in the equinox and December solstice and by dynamo current from migrating tides in the June solstice. Geomagnetic field configuration is the main reason for the longitudinal variation of IRC. The noon IRC have a wave-4 zonal structure, which is mainly caused by the outward propagation of migrating and nonmigrating tides. The dusk IRC in the western hemisphere shows a larger current density than that in the eastern hemisphere, resulting mainly from the neutral wind dynamo current. The competing effect of the wind dynamo current and polarization current determined the peak location of the total current in the western hemisphere.
Graphical Abstract
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227
Authors: Brahmer Julie R. , Lee Jong-Seok , Ciuleanu Tudor-Eliade , Bernabe Caro Reyes , Nishio Makoto , Urban Laszlo , Audigier-Valette Clarisse , Lupinacci Lorena , Sangha Randeep , Pluzanski Adam , Burgers Jacobus , Mahave Mauricio , Ahmed Samreen , Schoenfeld Adam J. , Paz-Ares Luis G. , Reck Martin , Borghaei Hossein , O'Byrne Kenneth J. , Gupta Ravi G. , Bushong Judith , Li Li , Blum Steven I. , Eccles Laura J. , Ramalingam Suresh S. 
Published: October 2022

PURPOSE We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic non–small-cell lung cancer, regardless of tumor programmed death ligand 1 (PD-L1) status. METHODS Adults with stage IV/recurrent non–small-cell lung cancer without EGFR mutations or ALK alterations and with tumor PD-L1 ≥ 1% or < 1% (n = 1739) were randomly assigned. Patients with tumor PD-L1 ≥ 1% were randomly assigned to first-line nivolumab plus ipilimumab, nivolumab alone, or chemotherapy. Patients with tumor PD-L1 < 1% were randomly assigned to nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy. End points included exploratory 5-year results for efficacy, safety, and quality of life. RESULTS At a minimum follow-up of 61.3 months, 5-year OS rates were 24% versus 14% for nivolumab plus ipilimumab versus chemotherapy (PD-L1 ≥ 1%) and 19% versus 7% (PD-L1 < 1%). The median duration of response was 24.5 versus 6.7 months (PD-L1 ≥ 1%) and 19.4 versus 4.8 months (PD-L1 < 1%). Among patients surviving 5 years, 66% (PD-L1 ≥ 1%) and 64% (PD-L1 < 1%) were off nivolumab plus ipilimumab without initiating subsequent systemic anticancer treatment by the 5-year time point. Survival benefit continued after nivolumab plus ipilimumab discontinuation because of treatment-related adverse events, with a 5-year OS rate of 39% (combined PD-L1 ≥ 1% and < 1% populations). Quality of life in 5-year survivors treated with nivolumab plus ipilimumab was similar to that in the general US population through the 5-year follow-up. No new safety signals were observed. CONCLUSION With all patients off immunotherapy treatment for ≥ 3 years, nivolumab plus ipilimumab increased 5-year survivorship versus chemotherapy, including long-term, durable clinical benefit regardless of tumor PD-L1 expression. These data support nivolumab plus ipilimumab as an effective first-line treatment for patients with metastatic non–small-cell lung cancer. [Media: see text]